Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185033 | 0.83 | NPC1 (0.43) | PREPPDK1PDK2PDK3PDK4 | |
| SCHEMBL29560191 | 0.80 | SMN1; SMN2 (0.45) | PREPPDK1PDK2PDK3PDK4 | |
| SCHEMBL13303248 | 0.79 | ACE2 (0.48) | ACE2PREPPDK1PDK2PDK3 | |
| SCHEMBL13303246 | 0.79 | ACE2 (0.48) | ACE2PREPPDK1PDK2PDK3 | |
| SCHEMBL12123905 | 0.78 | HTT (0.47) | PREPKLK7KLK5NPC1RAB9A | |
| SCHEMBL1326915 | 0.78 | HTT (0.47) | PREPKLK7KLK5NPC1RAB9A | |
| SCHEMBL29410727 | 0.78 | HTT (0.47) | PREPKLK7KLK5NPC1RAB9A | |
| SCHEMBL29510871 | 0.77 | PDK1 (0.44) | PREPPDK1PDK2PDK3PDK4 | |
| SCHEMBL29879078 | 0.77 | PREP (0.45) | ACE2PREPKLK7KLK5NPC1 | |
| SCHEMBL29302826 | 0.77 | PREP (0.45) | ACE2PREPKLK7KLK5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | ACE2 1553/4885PREP 2042/4885KLK7 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.